Feasibility
cognitive decline, early‐stage breast cancer
RECRUITMENT, SIDE EFFECT
Of the 412 patients screened, 126 were eligible and approached, and 56 enrolled (recruitment rate: 44%; Figure Modified CONSORT flow diagram for a single‐arm trial of memantine to prevent cognitive decline during chemotherapy for early‐stage breast cancer.On average, participants were scheduled for 22 weeks of memantine (SD 9.3). Thirty‐nine participants (76%) reported ≥90% adherence with scheduled doses, two participants (4%) reported 50%–89% adherence, and 10 participants (20%) reported <50% adherence. Independent of overall adherence, 12 participants (24%) discontinued memantine prior to the end of the study. Reasons for discontinuation included side effect concerns by the participant, provider, or study team regardless of formal attribution to memantine (